Loading stock…

DiaSorin S.p.A. (DIA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

DiaSorin S.p.A.

DIAMarket cap $4.25BPrice $85.9

Country🇮🇹Italy

SectorHealthcare

IndustryHealthcare Equipment

Makes diagnostic testing kits and instruments that labs and hospitals use to detect diseases, from infections to vitamin deficiencies. This Italian company became a household name during COVID for developing one of the first molecular tests for the virus.

In Bastion Portfolios?

52W Return0%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-1%2

Revenue Forecast

Rev CAGR (1y)-2%2

Rev CAGR (3y)+5%4

Rev CAGR (5y)+5%5

Earnings Forecast

EPS Growth Y+1na–

EPS Growth Y+2+11%7

EPS Growth Y+3+8%6

Quality

Margins

EBIT Margin22%8

Net Income Margin12%6

Free Cash Flow Margin20%8

Debt

Net Debt/EBITDA2.44

Efficiency

ROE10%4

ROA5%6

Earnings Stability55

GEAR+

Not enough data to calculate the GEAR+ rating.

Value

Price Multiples

P/E Ratio (Forward)194

P/E Ratio (Forward 3y)155

P/BV2.75

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd165

Yield

Free Cash Flow Yield6.3%7

Dividend Yield1.7%5

Momentum

Short term

1 month return+4%9

3 month return+15%9

YTD return+13%7

Mid term

Price vs 52wHigh96%10

1 year return-2%4

Long term

3 year return-9%2

5 year return-53%1

Risk Shield

Price Risk

Beta0.48

Volatility39%5

Free Cash Flow

Free Cash Flow Margin20%8

Free Cash Flow Yield6.3%7

Quality

ROCE11%6

Earnings Stability55

Net Debt/EBITDA2.44

02Growth

Is it actually growing, and how fast?

DIADiaSorin S.p.A.

Revenue FY25$1.4B

GROWTH RATING↗

——

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%2

Revenue, next 1Y-2%2

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26Ena–

EPS growth, FY27E+11%7

EPS growth, FY28E+8%6

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 5%/yr from here.

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 5%/yr).

WATCH

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Growth is the weak spot here, trailing 100% of companies worldwide.

Revenue fell 1%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

DIADiaSorin S.p.A.

Total return Current58.8%

Price return Current45.0%

MOMENTUM RATING↗

AVERAGE60 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+15%9

YTD return+13%7

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return-2%4

3-year return-9%2

5-year return-53%1

MOMENTUM ASSESSMENT

STRENGTHS

It's down 2% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+15%) and so far this year (+13%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-9.2% over three years and -53% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on DiaSorin. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

DIADiaSorin S.p.A.

Revenue FY25$1.4B

GROWTH RATING↗

——

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%2

Revenue, next 1Y-2%2

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26Ena–

EPS growth, FY27E+11%7

EPS growth, FY28E+8%6

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 5%/yr from here.

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 5%/yr).

WATCH

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Growth is the weak spot here, trailing 100% of companies worldwide.

Revenue fell 1%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

DIADiaSorin S.p.A.

Total return Current58.8%

Price return Current45.0%

MOMENTUM RATING↗

AVERAGE60 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+4%9

3-month return+15%9

YTD return+13%7

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return-2%4

3-year return-9%2

5-year return-53%1

MOMENTUM ASSESSMENT

STRENGTHS

It's down 2% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+4%), over three months (+15%) and so far this year (+13%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-9.2% over three years and -53% over five), behind 80% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on DiaSorin. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community